spacer
home > ebr > summer 2017 > cut and paste
PUBLICATIONS
European Biopharmaceutical Review

Cut and Paste

The successful sequencing of the human genome in 2003 was a momentous accomplishment and has turned out to be a gift that keeps on giving. A renewed understanding of biology and pathophysiology has advanced the knowledge and utility of many existing fields, such as rare diseases, genetic disorders and cancer, to name but three. As a result, there has been an explosion of new techniques to diagnose, prevent and treat pathologies. This singular event has also led to the spawning of new areas like next-generation sequencing and gene-editing. The latter is a disruptive emerging technology that has the potential to alter the way we view genetic or gene-related diseases, changing many from being lethal to chronic at worst and curable at best.

CRISPR-Cas9


Heraclitus, a Greek philosopher, is credited with saying that ‘change is the only constant in life’; in science, this continues to prove true. In the 90s, gene therapy was hailed as the next big thing at the cutting edge of science. Revolutionary as it was, it has stuttered and spluttered, failing to break into the realms of mainstream therapies. Gene therapy involves using a neutered virus (known as a viral vector) to deliver a synthetic functioning copy of a gene into cells. The trouble is that there is no control over where the gene will end up in the three billion DNA base pairs, hence it is a rather blunt instrument.

While gene therapies were still experiencing teething problems, two bacteriologists serendipitously discovered a process that would progress genetic science. They observed that bacteria, when defending themselves from a virus, would replicate the virus’s DNA and attach a key enzyme called Cas9. This would then unlock the DNA of the virus, break and disable it, thereby rendering the virus impotent. Mimicking this clever process from nature, clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 technology was born.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jimmy Muchechetere is a Healthcare and Biotech Research Analyst at Investec, having joined the financial industry in 2011 at Williams De Broë (now Investec Wealth & Investment) as a Research Intern. He is responsible for the equity research of all pharma as well as other healthcare and biotech companies across the globe. Jimmy also oversees the smooth running of the research department’s international service and is a registered medical doctor with seven years’ experience.
spacer
Jimmy Muchechetere
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RWS Life Sciences Welcomes New VP of Quality

RWS Life Sciences welcomes Clarice Streets, ASQ, CMQ, OE, as Vice President, Global Quality and Process, in charge of the strategic direction and implementation of its Quality system, underlying organizational processes, and change management.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 
Industry Events

Synthetic Biology Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its Synthetic Biology Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement